Supernus Pharmaceuticals 경영진
경영진 기준 점검 2/4
Supernus Pharmaceuticals CEO는 Jack Khattar, Jan2005 에 임명되었습니다 의 임기는 21.67 년입니다. 총 연간 보상은 $15.50M, 6.7% 급여 및 93.3% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $92.29M 가치에 해당하는 회사 주식의 3.81% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 6.6 년과 14.1 년입니다.
핵심 정보
Jack Khattar
최고경영자
US$15.5m
총 보수
| CEO 급여 비율 | 6.68% |
| CEO 재임 기간 | 21.7yrs |
| CEO 지분 보유율 | 3.8% |
| 경영진 평균 재임 기간 | 6.6yrs |
| 이사회 평균 재임 기간 | 14.1yrs |
최근 경영진 업데이트
Recent updates
Seeking Alpha • Aug 03
Supernus And Indivior Merger: There May Be Some Skepticism, But I Have Faith In This Deal
Summary Supernus Pharmaceuticals will merge with Indivior in a tax-free all-stock deal, creating a CNS-focused company with $2.2bn pro forma revenues. The combined entity expects $125m in annual cost synergies, a robust commercial portfolio of 11 medicines, and a net leverage ratio below 1x post-merger. SUPN's Qelbree and INDV's Sublocade franchises drive growth; SUPN's Q2 revenues rose 35% YoY, while INDV's Sublocade sales grew over 20% YoY. I see the merger as a strategic leap, increasing cash flow and scale, with potential for further value-enhancing deals and accelerated growth. Read the full article on Seeking Alpha
내러티브 업데이트 • Jun 24
SUPN: Consistent 2026 Guidance And Margins Will Support Forward Repricing
Analysts have maintained their $62.83 price target on Supernus Pharmaceuticals, citing consistent assumptions for revenue growth, profit margin, discount rate, and future P/E in their latest update. What’s in the News for Supernus Pharmaceuticals Supernus Pharmaceuticals reiterated full year 2026 total revenue guidance in the range of US$840 million to US$870 million, including ONAPGO net sales of US$45 million to US$70 million and Trokendi XR and Oxtellar XR net sales of US$40 million to US$50 million.내러티브 업데이트 • Jun 09
SUPN: Steady 2026 Guidance And Earnings Outlook Will Support Forward Repricing
Analysts have held their price target for Supernus Pharmaceuticals steady at $62.83. This reflects only fine tuned adjustments to revenue growth, profit margin assumptions, and future P/E that leave their overall valuation view unchanged.내러티브 업데이트 • May 26
SUPN: Resolved Supply Constraints Will Support Forward Repricing Case
Analysts have raised their price target on Supernus Pharmaceuticals stock to $65 from $60, citing updated models after Q4 results and increased confidence that Onapgo supply constraints are easing as additional production capacity comes online. Analyst Commentary Bullish Takeaways Bullish analysts view the higher US$65 price target as reflecting updated Q4 assumptions and a clearer picture of the company’s earnings power.내러티브 업데이트 • May 11
SUPN: Easing Supply Constraints Will Support Future Repricing Opportunity
Analysts have inched their price target for Supernus Pharmaceuticals higher to $65, supported by refreshed models that factor in updated fair value estimates, modestly different growth and margin assumptions, and greater confidence that Onapgo supply constraints are easing. Analyst Commentary Bullish Takeaways Bullish analysts view the higher US$65 price target as reflecting updated fair value work, where refreshed assumptions on growth and margins support a stronger long-term earnings profile.내러티브 업데이트 • Apr 22
SUPN: Resolved Supply Constraints Will Support Future Repricing Potential
Analysts have lifted their price target on Supernus Pharmaceuticals by $5 to $65, citing refreshed models after Q4 results and improved visibility on Onapgo supply as production ramps up with the current supplier and a second source expected in 2027. Analyst Commentary Bullish Takeaways Bullish analysts view the $65 price target, up from $60, as reflecting refreshed forecasts after the latest Q4 update.내러티브 업데이트 • Apr 07
SUPN: Resolved Supply Constraints And Dual Sourcing Plans Will Support Future Repricing
Narrative Update: Supernus Pharmaceuticals Analyst Price Target Shift Analysts have lifted their price target on Supernus Pharmaceuticals to $65 from $60, citing updated models after Q4 results and expectations that Onapgo supply constraints are now addressed with increased production capacity and a planned second supplier in 2027. Analyst Commentary Analysts see the updated price target as a reflection of fresh Q4 inputs and improved visibility on Onapgo supply.내러티브 업데이트 • Mar 24
SUPN: Resolved Supply Constraints Will Support Repricing Through Improved Execution
Analysts have lifted their price target on Supernus Pharmaceuticals to $65 from $60, citing updated models after Q4 results and expectations that Onapgo supply constraints are easing with increased production capacity and an additional supplier planned for 2027. Analyst Commentary Bullish Takeaways Bullish analysts see the higher US$65 price target as a reflection of updated models that better align with recent Q4 information and current expectations for the business.내러티브 업데이트 • Mar 10
SUPN: Supply Resolution And Refined P/E Assumptions Will Support Repricing
Analysts have increased their price target on Supernus Pharmaceuticals to $65 from $60, citing updated models following Q4 results and expectations that Onapgo supply constraints are now resolved with expanded production capacity. Analyst Commentary Bullish Takeaways Bullish analysts see the higher US$65 price target as a reflection of updated Q4 assumptions that support their view of improved execution and earnings potential.내러티브 업데이트 • Feb 23
SUPN: Stable Fair Value And Refined P/E Assumptions Will Support Repricing
Analysts modestly adjusted their $61.33 price target on Supernus Pharmaceuticals as they updated their assumptions around revenue growth, profit margin, and future P/E. This reflects a more finely tuned view of the company’s earnings power and valuation risk.내러티브 업데이트 • Feb 09
SUPN: Steady Fair Value And P/E Outlook Will Support Bullish Repricing
Analysts have kept their price target for Supernus Pharmaceuticals broadly steady, citing only modest tweaks to underlying assumptions such as a slightly higher discount rate, minor adjustments to expected revenue growth and profit margin, and a largely unchanged future P/E outlook. Valuation Changes Fair Value Estimate remains unchanged at 61.33.내러티브 업데이트 • Jan 25
SUPN: Higher 2025 Revenue Guidance Will Support Expanded Future Earnings Multiple
Analysts have adjusted their price target on Supernus Pharmaceuticals to US$61.33 per share, reflecting updated assumptions around discount rate, revenue growth, profit margin, and future P/E that remain broadly in line with prior estimates. What's in the News Supernus Pharmaceuticals raised its 2025 total revenue guidance to a range of US$685 million to US$705 million, including approximately US$75 million to US$85 million from Trokendi XR and Oxtellar XR (Key Developments).내러티브 업데이트 • Jan 10
SUPN: Higher 2025 Revenue Guidance Will Support Expanded Future Earnings Multiple
Analysts have inched their price target on Supernus Pharmaceuticals higher by about $0.83, citing updated assumptions that include a modest adjustment to fair value, slightly different revenue growth and profit margin expectations, and a higher future P/E multiple. What's in the News Supernus Pharmaceuticals raised its 2025 total revenue guidance to a range of US$685 million to US$705 million, including approximately US$75 million to US$85 million from Trokendi XR and Oxtellar XR (Key Developments).내러티브 업데이트 • Dec 19
SUPN: Faster Therapy Adoption Will Drive Shares Toward Higher Future Upside
Analysts have raised their price target on Supernus Pharmaceuticals to $65, up from $40, citing a faster than expected ramp for ONAPGO and the potential for additional upside beyond current peak sales assumptions. Analyst Commentary Recent research updates reflect a constructive shift in sentiment toward Supernus, with multiple firms lifting price targets and emphasizing the upside from ONAPGO's adoption curve.내러티브 업데이트 • Dec 05
SUPN: Upgrades Will Drive Future Upside As Revenue Outlook Tightens
Analysts have raised their price target on Supernus Pharmaceuticals to $65 from $40, reflecting growing confidence in stronger ONAPGO uptake and expanded long term earnings potential. Analyst Commentary Recent Street research reflects a more constructive stance on Supernus, with higher price targets supported by improving ONAPGO assumptions and a clearer long term earnings trajectory.내러티브 업데이트 • Nov 20
SUPN: Upgrades Will Drive Momentum As Earnings Guidance Increases
Analysts have raised their price target for Supernus Pharmaceuticals from $59.33 to $60.50, citing improved revenue growth expectations and increased peak sales forecasts for ONAPGO. Analyst Commentary Recent Street research reflects growing optimism around Supernus Pharmaceuticals, as analysts adjust their targets and ratings in response to strong expectations for ONAPGO and the company’s broader growth trajectory.내러티브 업데이트 • Nov 05
SUPN: Upgrades And Revenue Outlook Will Shape Performance Amid Execution Risk
Analysts have raised their price target for Supernus Pharmaceuticals by over $4 to approximately $59.33 per share. This change is due to higher future revenue growth expectations and an improved outlook for key therapies.내러티브 업데이트 • Oct 22
Analysts Boost Price Targets for Supernus Pharmaceuticals on Accelerating Growth and Revenue Outlook
Supernus Pharmaceuticals’ analyst price targets have risen sharply, with the fair value estimate increasing from $49.20 to $55.20 per share as analysts cite accelerating growth prospects and higher peak sales potential in key product lines. Analyst Commentary Bullish Takeaways Bullish analysts have raised their price targets substantially, with figures as high as $65 per share.내러티브 업데이트 • Oct 08
Widening CNS Access Will Shape Long-term Market Opportunity
Analysts have raised their fair value estimate for Supernus Pharmaceuticals from $40.20 to $49.20, citing a stronger forecast for blockbuster products and higher projected profit margins. This has resulted in a more than $9 increase in their price target.분석 기사 • Sep 10
We Ran A Stock Scan For Earnings Growth And Supernus Pharmaceuticals (NASDAQ:SUPN) Passed With Ease
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...분석 기사 • Jul 23
Benign Growth For Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Underpins Its Share Price
Supernus Pharmaceuticals, Inc.'s ( NASDAQ:SUPN ) price-to-sales (or "P/S") ratio of 3.1x might make it look like a buy...분석 기사 • May 13
Shareholders Can Be Confident That Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings Are High Quality
Supernus Pharmaceuticals, Inc. ( NASDAQ:SUPN ) just reported healthy earnings but the stock price didn't move much...분석 기사 • Feb 10
Investor Optimism Abounds Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) But Growth Is Lacking
With a price-to-earnings (or "P/E") ratio of 35.5x Supernus Pharmaceuticals, Inc. ( NASDAQ:SUPN ) may be sending very...Seeking Alpha • Feb 06
Supernus: New Approval Holds Promise Of Increased Growth
Summary Supernus Pharmaceuticals' ONAPGO for Parkinson’s Disease received FDA approval, providing a basis for optimism despite past regulatory challenges with SPN-830. The company is methodically planning ONAPGO's market launch in Q2 2025, supported by a robust nurse education program and access support. Continuous subcutaneous apomorphine infusion has a proven 30-year history in Europe, bolstering confidence in ONAPGO's potential success. Supernus' unsteady earnings and unproductive pipeline make it challenging to value, but ONAPGO's approval marks a significant positive development. Read the full article on Seeking AlphaSeeking Alpha • Nov 12
Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth
Summary Supernus Pharmaceuticals recently posted better-than-expected Q3 results, and management also revised FY2024 guidance upward. The ADHD drug Qelbree, which was approved in 2021, is powering revenue growth, and reduced costs are benefiting the bottom line. The company also has a pristine balance sheet with just over $400 million in cash and marketable securities. An updated analysis around Supernus Pharmaceuticals is provided in the paragraphs below. Read the full article on Seeking Alpha분석 기사 • Oct 31
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk
With a median price-to-sales (or "P/S") ratio of close to 2.9x in the Pharmaceuticals industry in the United States...
새로운 내러티브 • Sep 12
Qelbree And GOCOVRI Spearhead Robust Revenue Surge, Setting The Path For Market Domination In CNS Therapeutics
Supernus Pharmaceuticals shows robust growth potential with advancements in its product pipeline and significant net sales growth from key products like Qelbree and GOCOVRI.Seeking Alpha • Sep 12
Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives
Summary Supernus Pharmaceuticals' stock has risen 15% since my last "strong buy" rating, despite recent analyst downgrades due to Qelbree's slowing growth. Supernus' diverse neuroscience portfolio includes key drugs like Qelbree for ADHD and GOCOVRI for Parkinson's, with Qelbree's revenues being potentially seasonally influenced. Despite falling sales of older drugs, Supernus' strong financial position and promising pipeline, including SPN-820 for depression, suggest significant future upside is achievable, but not inevitable. The market may undervalue Supernus, focusing on risks over potential, but strategic M&A and upcoming catalysts like SPN-820 data could drive substantial gains. Read the full article on Seeking Alpha분석 기사 • Aug 19
Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings
The market was pleased with the recent earnings report from Supernus Pharmaceuticals, Inc. ( NASDAQ:SUPN ), despite the...Seeking Alpha • Jul 02
Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout
Summary Supernus' revenue growth is hindered by rapidly declining Trokendi sales. There are no pipeline products reliably poised to help out with revenues. Qelbree provides the one bright point on Supernus' revenues. Read the full article on Seeking Alpha분석 기사 • Apr 24
Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price
There wouldn't be many who think Supernus Pharmaceuticals, Inc.'s ( NASDAQ:SUPN ) price-to-sales (or "P/S") ratio of...Seeking Alpha • Mar 04
Supernus Pharmaceuticals: Moving Through An 'Inflection Year'
Summary Today, we take an updated look at Supernus Pharmaceuticals, Inc. after its posted better-than-expected Q4 results last week. The company will be going through an inflection year in 2024 as one core product faces declining sales while two new compounds see considerable sales growth. Supernus used to 2023 to pay off its convertible note obligations and has a debt-free balance sheet with more than $270 million in cash and marketable securities on it. What is ahead for this biopharma company in 2024. An analysis follows in the paragraphs below. Read the full article on Seeking AlphaCEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$110m |
| Mar 31 2026 | n/a | n/a | -US$29m |
| Dec 31 2025 | US$16m | US$1m | -US$39m |
| Sep 30 2025 | n/a | n/a | -US$19m |
| Jun 30 2025 | n/a | n/a | US$64m |
| Mar 31 2025 | n/a | n/a | US$62m |
| Dec 31 2024 | US$13m | US$1m | US$74m |
| Sep 30 2024 | n/a | n/a | US$60m |
| Jun 30 2024 | n/a | n/a | US$5m |
| Mar 31 2024 | n/a | n/a | -US$16m |
| Dec 31 2023 | US$13m | US$963k | US$1m |
| Sep 30 2023 | n/a | n/a | US$26m |
| Jun 30 2023 | n/a | n/a | US$43m |
| Mar 31 2023 | n/a | n/a | US$52m |
| Dec 31 2022 | US$10m | US$914k | US$61m |
| Sep 30 2022 | n/a | n/a | US$38m |
| Jun 30 2022 | n/a | n/a | US$57m |
| Mar 31 2022 | n/a | n/a | US$73m |
| Dec 31 2021 | US$8m | US$870k | US$53m |
| Sep 30 2021 | n/a | n/a | US$82m |
| Jun 30 2021 | n/a | n/a | US$100m |
| Mar 31 2021 | n/a | n/a | US$111m |
| Dec 31 2020 | US$7m | US$836k | US$127m |
| Sep 30 2020 | n/a | n/a | US$129m |
| Jun 30 2020 | n/a | n/a | US$118m |
| Mar 31 2020 | n/a | n/a | US$116m |
| Dec 31 2019 | US$8m | US$812k | US$113m |
보상 대 시장: Jack의 총 보수(USD15.50M)는 US 시장에서 비슷한 규모 기업의 평균(USD6.99M)보다 높습니다.
보상과 수익: Jack의 보상은 회사가 적자임에도 증가했습니다.
CEO
Jack Khattar (65 yo)
21.7yrs
재임 기간
US$15,501,557
보수
Mr. Jack A. Khattar, M.B.A., founded Supernus Pharmaceuticals, Inc. (Formerly, Shire Laboratories, Inc.) in 2005 and has served as Chief Executive Officer, President, Secretary and Director since 2005. He...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Founder | 21.7yrs | US$15.50m | 3.81% $ 92.3m | |
| Senior VP & CFO | 5.1yrs | US$1.92m | 0.016% $ 380.2k | |
| Chief Scientific Officer & Senior VP of Intellectual Property | 14.5yrs | US$1.39m | 0.032% $ 776.0k | |
| Senior VP & Chief Technology Operations Officer | 6.7yrs | US$1.36m | 0.034% $ 813.7k | |
| Senior VP of Research & Development and Chief Medical Officer | 6.6yrs | US$1.45m | 0.024% $ 582.1k | |
| Compliance Officer | 14.7yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Sales | 11.7yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP & Chief Commercial Officer | less than a year | 데이터 없음 | 0.16% $ 3.9m | |
| Senior VP & Chief Business Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Supply Chain | 5.3yrs | 데이터 없음 | 데이터 없음 |
6.6yrs
평균 재임 기간
65yo
평균 나이
경험이 풍부한 관리: SUPN의 경영진은 노련하고 경험이 풍부합니다(평균 재임 6.6 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Founder | 21.7yrs | US$15.50m | 3.81% $ 92.3m | |
| Independent Chairman of the Board | 21.7yrs | US$417.01k | 0.21% $ 5.2m | |
| Independent Director | 11.5yrs | US$398.51k | 0.047% $ 1.1m | |
| Independent Director | 8.3yrs | US$376.01k | 0.047% $ 1.1m | |
| Independent Director | 16.7yrs | US$385.01k | 0.10% $ 2.5m | |
| Independent Director | 3.1yrs | US$362.51k | 데이터 없음 |
14.1yrs
평균 재임 기간
65.5yo
평균 나이
경험이 풍부한 이사회: SUPN의 이사회는 노련하고 경험이 풍부합니다(평균 재임 14.1 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/13 13:54 |
| 종가 | 2026/09/11 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Supernus Pharmaceuticals, Inc.는 17명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Emily Bodnar | Berenberg |
| Chi Meng Fong | BofA Global Research |
| Pavan Patel | BofA Global Research |